Loss of TP53 mediates suppression of Macrophage Effector Function via Extracellular Vesicles and PDL1 towards Resistance against Chemoimmunotherapy in B-cell malignancies
Izquierdo, E.; Vorholt, D.; Sackey, B.; Nolte, J.; Blakemore, S. J.; Schmitz, J.; Barbarino, V.; Nickel, N.; Bachurski, D.; Lobastova, L.; Nikolic, M.; Michalik, M.; Brinker, R.; Neuhaus, R.; Frenzel, L.; Koch, M.; Knittel, G.; Reinhardt, H. C.; Peifer, M.; Rebollido-Rios, R.; Bruns, H.; Krueger, M.; Hallek, M.; Pallasch, C.
Show abstract
Chemoimmunotherapy (CIT) is the standard of care in B-cell malignancies. It is relying on synergistic effects of alkylating chemotherapy and monoclonal antibodies via secretory crosstalk with effector macrophages. Here, we observed that loss of p53 function mediates resistance to CIT by suppressing macrophage phagocytic function. Loss of p53 leads to an upregulation of PDL1 and an increased formation of extracellular vesicles (EVs). EVs directly inhibit macrophage phagocytosis by PDL1 surface expression. Suppression of phagocytic function by lymphoma cell-derived EVs could be abrogated by pre-incubation of EVs with anti-PDL1 antibodies, CRISPR-KO of PDL1 and abrogation of EV formation by RAB27A-KO in lymphoma cells. Immune checkpoint inhibition represents a viable strategy to overcome EV-mediated resistance to chemoimmunotherapy in lymphoma. SignificanceLoss of TP53 mediates cell autonomous resistance to genotoxic chemotherapy, moreover non-cell autonomous effects may cause therapy resistance mediated by the tumor microenvironment. We identify a TP53-dependent mechanism that mediates resistance to synergistic chemoimmunotherapy by increasing formation of EVs and expression of the PDL1 immune checkpoint. PDL1 on EVs is directly responsible for macrophage suppression, preventing the exertion of the essential effector function of antibody-dependent cellular phagocytosis. This novel mechanism of resistance is in turn targetable by PDL1 checkpoint inhibition. Enhanced EV-release and immune checkpoint expression in lymphoma are novel mechanisms of macrophage modulation in the lymphoma microenvironment. We provide a novel principle of resistance to chemoimmunotherapy (CIT) representing of immediate relevance to treatment of refractory B-cell lymphoma. HighlightsO_LILoss of TP53 in B-cell lymphoma induces resistance towards chemoimmunotherapy (CIT) by inhibition of macrophage effector function through PDL1 upregulation C_LIO_LILoss of TP53 increases formation of extracellular vesicles (EVs) carrying PDL1 C_LIO_LIEVs inhibit antibody-mediated cellular phagocytosis (ADCP), a key macrophage effector function in CIT C_LIO_LITargeting PDL1 on EVs with immune checkpoint inhibitors overcomes TP53-mediated resistance to CIT C_LI
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity 95%
- Reprogramming and redifferentiation of mucosal-associated invariant T cells reveals tumor inhibitory activity 95%
- CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals 94%
Similar papers in this journal
- ATP citrate lyase is an essential player of the metabolic rewiring induced by PTEN loss during T-ALL development. 95%
- Single-cell profiling identifies clinically relevant interactions between tumor associated macrophages and blood endothelial cells in diffuse large B cell lymphoma 95%
- Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies 94%
Similar papers in this journal
- Potent clinical predictive and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer 94%
- Regulation of Leucine-Rich Repeat Kinase 2 by inflammation and IL-4 94%
- Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca2+-dependent death of cancer cells 94%
Similar papers in this journal
Similar papers in this journal
- Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression 96%
- Integrated signaling and transcriptome analysis reveals Src-family kinase individualities and novel pathways controlled by their constitutive activity 95%
- Extrafollicular responses are sufficient to drive initiation of autoimmunity and early disease hallmarks of lupus 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.